2019 – Page 6 – Policy & Medicine

FDA Says More Orphan Drug Labels Need Pediatrics Info

FTC Warns Law Firms About Potentially Deceptive Claims in TV Ads

OIG Report Concludes that DEA was Slow to Respond to Opioid Diversion Crisis

FDA OPDP Issues Warning Letter to Galt Pharmaceuticals Regarding Insomnia Drug Marketing

“Pay for Delay” Legislation Signed in California

When Money and Doritos Don’t Suffice – The Crucial Imperative for Integrating Effective Compliance Controls in the Ongoing Opioid Settlements.

FDA ANDA Review and Approval Metrics Improving, But Much Work Remains

FDA OPDP Issues Warning Letter to Metuchen Pharma About ED Drug Advertising

How Are Insurers Treating the $2M Drug, Zolgensma?

Nevada Fines Drug Manufacturers for Failure to Comply with Drug Transparency Law